BAG Dres. med. Quist PartG
- Address
- Haifa-Allee 20, 55128 Mainz, Germany
Immune System Diseases
The research at BAG Dres. med. Quist PartG targets immune‑mediated disorders, with a primary focus on hidradenitis suppurativa, a chronic inflammatory condition that often resists standard anti‑TNF therapy.
- Evaluation of JAK inhibition as a new treatment approach
- Investigation of oral agents for refractory disease
- Safety monitoring in patients with prior biologic exposure
The Mainz site collaborates with academic partners to expand therapeutic options for patients who have limited responses to existing therapies.
Skin and Connective Tissue Diseases
Studies conducted at the Mainz location concentrate on moderate‑to‑severe hidradenitis suppurativa within the broader category of skin and connective tissue diseases, aiming to discover effective interventions for this challenging disease.
- Dose‑response exploration of the investigational compound LAD191
- Comparative efficacy versus placebo in a controlled setting
- Long‑term tolerability and safety assessments
With a single dedicated investigator, the site ensures meticulous oversight and rapid progress in advancing treatment strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Almirall S.A.1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in BAG Dres. med. Quist PartG
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis | Bristol-Myers Squibb Services Unlimited Company | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 1 | Unknown | 2025-12-09 | 2025-12-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.